Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Cash & Equivalents (2016 - 2025)

Nutex Health's Cash & Equivalents history spans 16 years, with the latest figure at $185.6 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 356.63% year-over-year to $185.6 million; the TTM value through Dec 2025 reached $185.6 million, up 356.63%, while the annual FY2025 figure was $185.6 million, 356.63% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $185.6 million at Nutex Health, up from $166.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $185.6 million in Q4 2025 and bottomed at $3.7 million in Q1 2021.
  • The 5-year median for Cash & Equivalents is $35.2 million (2021), against an average of $49.4 million.
  • The largest annual shift saw Cash & Equivalents skyrocketed 134014.16% in 2021 before it plummeted 35.77% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $36.1 million in 2021, then decreased by 5.16% to $34.3 million in 2022, then tumbled by 35.77% to $22.0 million in 2023, then soared by 84.71% to $40.6 million in 2024, then soared by 356.63% to $185.6 million in 2025.
  • Per Business Quant, the three most recent readings for NUTX's Cash & Equivalents are $185.6 million (Q4 2025), $166.0 million (Q3 2025), and $96.7 million (Q2 2025).